Will the Doctor Stop Smoking?! by Anaizi, Nasr
DOI: 10.4176/090110       Editorial        
  
  
 
Will the Doctor Stop Smoking?!  
 
Nasr Anaizi 
 
Department of Physiology and Pharmacology, University of Rochester School of Medicine, USA 
 
 
Key words: Smoking cessation, Nicotine replacement, Bupropion, Varenicline 
 
Cigarette smoking is frequently described as the most 
common preventable cause of death.  According to the 
World Health Organization (WHO), by the end of the 21st 
century one billion people will die of smoking-related 
diseases, cancer will be the number one killer worldwide 
by 2010, and by 2030 tobacco smoking will be responsible 
for 8 million deaths per year [1]. These grim forecasts 
stem primarily from the widespread tobacco consumption 
mainly in Asia and Africa. Cigarette smoke contains 
thousands of toxic chemicals many of which are 
carcinogenic, prothrombotic, and/or atherogenic. The 
destructive effects of smoking harm virtually every organ-
system in the body. In addition to lung cancer, smoking 
increases the risk  of a vast array of diseases including 
other cancers (gastroesophageal and nasopharyngeal), 
respiratory tract infections, chronic obstructive pulmonary 
disease (COPD), stroke, coronary artery disease, 
aneurysm, peripheral vascular disease, psoriasis, sudden 
infant death syndrome (SIDS), infertility, and sexual 
dysfunction. 
 
In the United States the number of smokers has steadily 
declined over the past twenty years to <25% of the adult 
population. This was the result of intense public 
awareness programmes, higher taxes, and smoking bans 
in public places. These measures were fueled in part by 
dramatic revelations regarding the deliberate recruitment 
by the tobacco companies of teenagers into the ranks of 
nicotine addicts through targeted, misleading 
advertisement campaigns. However, the alarmingly high 
number of smokers in the developing countries particularly 
in China, India, and the Arab countries, either remains 
high or is getting higher.  
 
More surprising is the smoking prevalence among 
physicians in different parts of the world. A 1995 study in 
Greece found between 40 and 55% of physicians smoked 
regularly more than 20 cigarettes per day [2]. In 
Alexandria (Egypt), approximately 50% of physicians still 
smoke [3] today. In Jordan's largest tertiary care hospital, 
44% of internists and 75% of the emergency 
department's physicians still smoke regularly; fortunately 
none of the pulmonologists in this hospital smokes [4]. 
However, in Poland approximately 10% of pulmonologist 
still smoke [5]. In northern Italy [6], smoking prevalence 
among general practitioner was found to be around 22% 
in 2006, and it has declined dramatically in Croatia 
(<20%), Turkey (<15%), and New Zealand (<15%) [7]. I 
am not aware of any published surveys or studies dealing 
with the prevalence of smoking among Libyan physicians 
and other healthcare workers, but anecdotal reports 
suggest that the habit is common in Libyan hospitals. 
However, some interesting data concerning smoking 
prevalence and attitude toward various forms of tobacco 
consumption among Libyan students have been recently 
published in a correspondence to this journal [8]. 
 
Physicians and healthcare professionals in general must 
play an active role in patient education and in establishing 
effective tobacco control policies. Smoking prevalence 
among physicians is an extremely important issue because 
there is evidence that the smoking status of physicians 
significantly influences their attitude toward smoking 
cessation and their ability to initiate and effectively pursue 
patient counseling on smoking [9]. Needless to say those 
physicians who still smoke should not rest until they have 
successfully kicked the habit. It is also imperative that the 
medical school curricula include extensive and repeated 
coverage of the subject, and that a national smoking 
cessation program be designed and implemented. The 
long-term rewards of such programs can not be 
overestimated both in terms of public health and national 
economy. In addition, every physician should make it a 
duty to follow up on initial patient consultation and make 
smoking cessation a topic of a brief and pointed discussion 
in every patient visit in order to reinforce the message and 
provide the moral support that patients are known to 
value highly. 
 
Some surveys showed that <30% of physicians believed 
in the utility of pharmacologic intervention in smoking 
cessation; this suggests that physicians have limited 
k n o w l e d g e  i n  t h i s  a r e a   p e r h a p s  d u e  t o   i n s u f f i c i e n t  
exposure  to the more recent literature. Patient education 
coupled with direct counseling and pharmacotherapy has 
proved effective in achieving complete nicotine 
independence. In the following, I summarize the major 
pharmacotherapeutic interventions that are often used to 
help smokers overcome the consequences of nicotine 
withdrawal (anxiety, irritability, and the inability to 
concentrate). It should be noted that the rate of success 
of pharmacotherapy is highly dependent on 
social/emotional support and consistent, repeated face-to-
face counseling by physicians and other healthcare 
professionals.  Weight gain is often a side effect of 
smoking cessation, but it can be effectively controlled 
through dietary changes and exercise. 
 
Nicotine Replacement Therapy (NRT) 
Although cigarette smoke delivers thousands of 
compounds into the smoker's lungs, its addictive 
properties are attributed almost entirely to nicotine. 
Nicotine binds to specific nicotinic acetylcholine receptors 
(nAchR) throughout the brain and in autonomic ganglia. It 
also binds to receptors in the nigrostriatal and mesolimbic 
dopaminergic neurons.  It triggers the release of many 
neurotransmitters and hormones, and like cocaine and 
amphetamine, nicotine is a strong stimulant of the 
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dopamine reward pathway in the midbrain. The 
development of nicotine dependence is thought to be 
related to stimulation of the dopamine projections to the 
nucleus accumbens.  Nicotine also enhances the smoker’s 
level of vigilance and ability to concentrate and react to 
stressful situations through its action on the locus ceruleus 
in the midbrain [9]. 
Breaking the cycle of dependency is the main challenge 
in smoking cessation, and NRT is designed to alleviate the 
immediate difficulties posed by withdrawal symptoms as 
the ex-smoker begins to adapt to the lack of nicotine. 
NRT products are now available in a variety of dosage 
forms including chewing gum, lozenges, transdermal 
patch, inhaler, and nasal spray. Dosing depends on the 
patient’s prior smoking habits and each product comes 
with full dosing guidelines. NRT may be problematic in 
patients susceptible to cardiac arrhythmias and must be 
used with caution. 
 
Bupropion (150-mg sustained release tablets): 
Bupropion is an antidepressant that acts by inhibiting 
the uptake of dopamine and norepinephrine by the 
neurons. Because bupropion lowers the seizure threshold, 
i t  s h o u l d  b e  u s e d  w i t h  c a u t i o n  i n  p a t i e n t s  w h o  h a v e  a  
history of seizures, bipolar disorder, or eating disorder, 
and in patients taking monoamine oxidase inhibitors 
(MAOIs). The therapy is usually started one week before 
quit date beginning with one tablet each morning for 3 
days, then the dose is increased to one tablet every 12 
hours. Therapy may be continued for 2 to 3 months 
depending on craving and withdrawal symptoms. 
Insomnia and dry mouth are the main side effects 
associated with the use of bupropion. 
 
Varenicline (Chantix): 
Although the exact mechanism responsible for the 
efficacy of varenicline in smoking cessation is unknown, 
the partial activation of a subtype of nAchRs may be 
involved. Thus, varenicline may help by occupying and 
partially activating the nicotine receptors in the brain. 
Treatment starts one week before quit date with an initial 
dose of 0.5 mg once daily in the morning for 3 days, then 
0.5 mg twice daily for 4 days, then 1 mg twice daily. 
Therapy may be continued for up to 3 months, and in the 
event of a relapse, it may be continued for 3 additional 
months. Side effects include nausea, sleep disturbances, 
and headache. A few patients experienced significant 
psychiatric symptoms including agitation, depression, and 
suicidal ideation/behaviour. Patients should be observed 
and therapy should be stopped if atypical behaviour is 
noted. Patients with pre-existing psychiatric illness should 
not be started on this medication. 
 
In summary 
Cigarette smoking poses a great, but preventable health 
risk and smoking prevalence is still unacceptably high 
among physicians and the general public. In view of the 
staggering cost of smoking in terms of human lives, 
physicians need to make every effort  to quit smoking and 
help their patients do the same. In addition to consistent 
and repeated counseling, the proper use of 
pharmacotherapeutic agents such as nicotine replacement 
therapy, bupropion, and varenicline has proven very 
helpful in achieving complete nicotine independence for 
many patients. Furthermore, a nationwide multifarious 
programme dedicated to smoking cessation should be a 
top priority for the national health administration. 
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